Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

However, Merck defended its drug, insisting that the data demonstrated significant clinical benefits for adults with refractory or unexplained chronic cough. The panel's vote could delay the ...

Merck filed for approval of gefapixant in March 2021 on the strength of a pair of phase 3 trials – COUGH-1 and COUGH-2 – which found that the drug reduced 24-hour cough frequency by 18% and 15 ...

It's worth noting that the agreement has been forged a few months after Merck suffered a setback in its attempt to secure FDA approval for a potentially first-in-class drug for chronic cough ...

Most pediatricians are aware of the more common causes of chronic cough, but sometimes unexpected cases come along that ...

The chronic and progressive inflammatory disease bronchiectasis is characterised by permanent bronchi dilation and by ...

Your genes can also play a role. Its symptoms include shortness of breath, wheezing, a lasting cough, and increased mucus. Like chronic bronchitis, emphysema is a type of COPD. You can have the ...

Background: Children presenting with chronic cough are common to the primary care physicians, but data on the etiology are scant. Methods: We evaluated 40 children (age range, 5 to 12 years ...

Treatments for a wet cough can depend on the cause, which may include the common cold, viral or bacterial respiratory infections, chronic lung conditions, allergies, or congestive heart failure.

It falls between an acute cough, which lasts less than 3 weeks, and a chronic cough, which lasts more than 8 weeks. There are various causes for a subacute cough, including infections, viruses ...

Merck (MRK) reachead $106.64 at the closing of the latest trading day, reflecting a +0.28% change compared to its last close. Visa, Netflix, Merck and Hovnanian are included in this Analyst Blog ...